Relafen Settlement Affirms Need For Tort Reform, GSK's Garnier Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Wholesalers maintain they were overcharged for Relafen while GSK patent litigation prevented generics from entering the market. GSK says wholesalers can earn higher margins on branded products.